Journal
NATURE MEDICINE
Volume 24, Issue 10, Pages 1536-+Publisher
NATURE PUBLISHING GROUP
DOI: 10.1038/s41591-018-0205-5
Keywords
-
Funding
- National Institute of Allergy and Infectious Disease (NIAID) [R01-AI091878]
- National Cancer Institute (NCI) [P50-CA190991]
- National Institutes of Health (NIH) Beau Biden Cancer Moonshot Initiative [R33CA225328]
- National Nature Science Foundation of China [81472648, 81500089, 81620108023, 81222031, 81773041, 31600733]
- Research on The Basis and Frontier of Chongqing [cstc2016jcyjA0049]
- NATIONAL CANCER INSTITUTE [R33CA225328, P50CA190991] Funding Source: NIH RePORTER
- NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI091878] Funding Source: NIH RePORTER
Ask authors/readers for more resources
Impaired immunity in patients with late-stage cancer is not limited to antitumor responses, as demonstrated by poor vaccination protection and high susceptibility to infection(1-3). This has been largely attributed to chemotherapy-induced impairment of innate immunity, such as neutropenia(2), whereas systemic effects of tumors on hematopoiesis and adoptive immunity remain incompletely understood. Here we observed anemia associated with severe deficiency of CD8(+) T cell responses against pathogens in treatment-naive mice bearing large tumors. Specifically, we identify CD45(+) erythroid progenitor cells (CD71(+)TER119(+); EPCs) as robust immunosuppressors. CD45(+) EPCs, induced by tumor growth-associated extramedullary hematopoiesis, accumulate in the spleen to become a major population, outnumbering regulatory T cells (T(reg)s) and myeloid-derived suppressor cells (MDSCs). The CD45(+) EPC transcriptome closely resembles that of MDSCs, and, like MDSCs, reactive oxygen species production is a major mechanism underlying CD45(+) EPC-mediated immunosuppression. Similarly, an immunosuppressive CD45(+) EPC population was detected in patients with cancer who have anemia. These findings identify a major population of immunosuppressive cells that likely contributes to the impaired T cell responses commonly observed in patients with advanced cancer.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available